Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod

Por Nakhaei-Nejad, Maryam, Barilla, David, Lee, Chieh-Hsin, Blevins, Gregg, Giuliani, Fabrizio
Publicado no Neurol Neuroimmunol Neuroinflamm (2017)

Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management

Por Dhesi, Sumandeep, Chu, Michael P., Blevins, Gregg, Paterson, Ian, Larratt, Loree, Oudit, Gavin Y., Kim, Daniel H.
Publicado no J Investig Med High Impact Case Rep (2013)

Regulatory T Cells are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis

Por Oh, Unsong, Blevins, Gregg, Griffith, Caitlin, Richert, Nancy, Maric, Dragan, Lee, C. Richard, McFarland, Henry, Jacobson, Steven
Publicado em 2009

Decision-making under explicit risk is impaired in multiple sclerosis: relationships with ventricular width and disease disability

Por Radomski, Ashley D, Power, Christopher, Purdon, Scot E, Emery, Derek J, Blevins, Gregg, Warren, Kenneth G, Fujiwara, Esther
Publicado no BMC Neurol (2015)

The anti-CD25 Antibody Daclizumab Inhibits Inflammation and Stabilizes Disease Progression in MS

Por Bielekova, Bibiana, Howard, Thomas, Packer, Amy N., Richert, Nancy, Blevins, Gregg, Ohayon, Joan, Waldmann, Thomas A., McFarland, Henry F., Martin, Roland
Publicado em 2009

Treatment with the phosphodiesterase type 4 inhibitor rolipram fails to inhibit blood brain barrier disruption in MS

Por Bielekova, Bibiana, Richert, Nancy, Howard, Thomas, Packer, Amy N., Blevins, Gregg, Ohayon, Joan, McFarland, Henry F., Stürzebecher, Claus-Steffen, Martin, Roland
Publicado em 2009

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Por Bielekova, Bibiana, Richert, Nancy, Howard, Thomas, Blevins, Gregg, Markovic-Plese, Silva, McCartin, Jennifer, Würfel, Jens, Ohayon, Joan, Waldmann, Thomas A., McFarland, Henry F., Martin, Roland
Publicado em 2004